Zoetis Releases 2022 Sustainability Report to Share Progress in Building a Better Future for People, Animals and the Planet
-
in corporate giving invested in communities, and an additional$7.4 million distributed through Zoetis Foundation grants to support veterinarians and farmers$5.7 million -
Continued progress toward colleague diversity aspirations, including increased representation of women at the director level and above globally from
32% in 2020 to37% in 2022, aspiring to reach40% by 2025 - Received approval for several livestock vaccines in additional markets, which support reducing the need to use antibiotics
-
Achieved target to reduce energy intensity in manufacturing and R&D
5% by 2025, with a13.5% reduction -
Outlined roadmap to carbon neutrality by 2030, and
31% of manufacturing sites operating with100% renewable electricity
“In our third year of reporting to our Driven to Care aspirations and targets, we continue to make significant progress in our journey toward building a healthier future for our communities, animals and the planet,” said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. “The progress we’ve made toward our sustainability commitments would not be possible without the dedication, creativity and innovation of our colleagues who champion our purpose by contributing to a better future for us all.”
Communities – Care and Collaboration
Zoetis invested
The report also highlights progress made since 2020 toward the company’s diversity, equity and inclusion (DE&I) aspirations for 2025, including:
-
Increased representation of women at the director level and above globally from
32% to37% , aspiring to reach40% by 2025 -
Increased representation of Black colleagues in the
U.S. from4.0% to4.8% , aspiring to reach5% by 2025 -
Increased representation of people of color at all levels in the
U.S. from21.0% to24.6% , aspiring to reach25% by 2025 -
Increased representation of Latinx colleagues from
5.0% to6.4% , exceeding our aspiration of reaching6% by 2025
The Zoetis executive team is now
As part of ongoing efforts to support colleagues, Zoetis signed on to PrideVMC’s Gender Identity Bill of Rights (GIBOR), a document that affirms the rights of transgender, non-binary, and gender non-conforming persons, and provides guidance on how workplaces can support their employees by identifying and eliminating discriminatory practices. Zoetis engaged with 1,236 global active members across eight Colleague Resource Groups and launched Cultural Explorer training in eight languages to encourage respectful curiosity and open conversation about differences to deepen mutual understanding and value for colleagues’ unique contributions to the workplace.
Animals - Innovation in Animal Health
With the world’s population approaching the United Nations projected 10 billion people by 2050, some of our greatest challenges are emerging at the intersection of human, animal, environmental and economic health. By enhancing the health of livestock, innovative solutions can help contribute to the economic and environmental well-being of farmers and communities as well as support global food security.
In 2022, Zoetis received approval for several livestock vaccines in additional markets, which support the Health for Animals Roadmap to Reducing the Need for Antibiotics. This includes recombinant vector vaccines in
Zoetis reported progress on five years of its African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative with the aim to help improve livestock health and positively impact farmers’ livelihoods in Sub-Saharan Africa. At the completion of the initiative, Zoetis trained over 30,000 farmers, veterinary professionals, distributors and lab personnel –
Planet – the Drive to Protect our Planet
To reduce GHG emissions throughout the company’s operations and manage climate risks, Zoetis set a goal in 2022 to achieve carbon neutrality in its own operations by 2030, with a focus on Scope 1 and 2 emissions from its manufacturing and R&D operations, office locations and fleet vehicles. Aligned with its RE100 commitment, Zoetis reported
The company continued to take meaningful steps to reduce its environmental footprint and improve its products’ environmental impact throughout their life cycle in markets around the world. The report highlights initiatives in
For more detailed disclosure on the company’s ESG programs, practices and policies, please see zoetis.com/sustainability or download Zoetis’ 2022 Sustainability Report. Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care goals, and report annually.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of
DISCLOSURE NOTICES
Forward-Looking Statements: This press release and the 2022 Sustainability Report (including the 2022 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our sustainability, energy and climate goals, targets and plans; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2023 Zoetis Services LLC. All rights reserved.
ZTS-COR
ZTS-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20230614296226/en/
Media Contacts:
Christina Lood
1-973-822-7249 (o)
christina.lood@zoetis.com
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com
Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com
Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com
Source: Zoetis Inc.